Abstract
The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Current Pharmaceutical Design
Title: Bradykinin Antagonists as Anti-Cancer Agents
Volume: 9 Issue: 25
Author(s): J. M. Stewart
Affiliation:
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Abstract: The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Export Options
About this article
Cite this article as:
Stewart M. J., Bradykinin Antagonists as Anti-Cancer Agents, Current Pharmaceutical Design 2003; 9 (25) . https://dx.doi.org/10.2174/1381612033454171
DOI https://dx.doi.org/10.2174/1381612033454171 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) The Anabolic Effects of Growth Hormone (GH) and GH Secretagogues on Bone Mass and Density
Medicinal Chemistry Reviews - Online (Discontinued) Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs
Current Pharmaceutical Biotechnology Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Hetero-Diels-Alder Reactions in the Synthesis of Biologically Active Nitrogen Compounds: A Review
Current Organic Synthesis Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Multi-target Pharmacological Effects of Platycodin D
Mini-Reviews in Organic Chemistry Withdrawal Notice: Preparation and Applications of Glyconanoparticles
Current Drug Targets